Tolterodine



Urinary incontinence UI ; is a common and distressing condition estimated to affect 17 million women in the US. A recent paper reviewed its management in women Drugs Ther Perspect 2007; 23: 10-3 ; . There are three main types: Urgency UI involuntary leakage of urine, accompanied or immediately preceded by urgency ; is mainly caused by overactivity of the detrusor muscle, due to either excitability of the smooth muscle or neurological damage; Stress UI involuntary leakage of urine on effort, exertion, sneezing or coughing ; is due to sphincter incompetence caused by urethral weakness and or bladder neck hypermobility from childbirth or postmenopausal involution of the urethra Mixed UI is a combination of stress UI and urge UI either stress- or urgencypredominant ; . Diagnosis includes a detailed history and examination, urinalysis, completion of a frequency volume urine chart and disease-specific Quality-of-Life questionnaire and measurement of flow rate and post-void residual volume. This should differentiate between the different types of UI. Imaging studies and or cystoscopy are not usually required unless other pathologies are suspected. Treatment: The main aim in urgency UI is to reduce detrusor contraction and increase bladder capacity; in stress UI the aim is to increase urethral closing pressure by increasing urethral smooth and striated muscle tone. Mixed UI is more difficult to treat. First-line therapy for all three types of UI should include bladder training and pelvic floor exercises which requires co-operation from the patient. Lifestyle interventions including weight loss, exercise and smoking cessation are also recommended although there is little hard clinical evidence for their efficacy. Antimuscarinic agents, including oxybutynin, tolterodine and trospium, are the preferred pharmacological therapy for urgency UI. Adverse effects include dry mouth, constipation, blurred vision and dizziness. Duloxetine, which is a serotonin noradrenaline reuptake inhibitor, is licensed for stress UI; studies showed duloxetine in combination with pelvic floor exercises was more effective than either treatment alone. Adverse effects include nausea, dry mouth, constipation, fatigue and headache. In patients with mixed UI, initial drug therapy should target the most predominant symptoms, although in clinical practice antimuscarinic agents may be used as first-line irrespective of whether the UI is stress or urgency predominant. Other pharmacological agents have been used in the management of UI, but further research is needed. These include oestrogen for the treatment of stress UI in combination with pelvic muscle exercises ; and desmopressin. If pelvic floor exercises in combination with pharmacological treatment are not effective for mixed UI, urodynamic assessment and referral to a specialist is recommended. Surgical options are available but the risks of surgery must be weighed against potential benefits for the patient.

Headache, which were most frequent with tolterodine 23.4% and 9.4%, respectively ; , followed by YM178 13.8% and 6.9%, respectively ; and placebo 3.0% both ; : - Dizziness and palpitations tended to be more common with YM178, compared with placebo or tolterodine; most were considered treatment-related. Egyptian medicine seems to have had the most lasting influence on the later development of medicine, through the medium of the Greeks. quoted Greek historian and traveller, Herodotus 5BC ; where he commented on medical practices in Egypt; "the art of healing is with them divided up, so that each physician treats one ailment and no more. Egypt is full of physicians, some treating diseases of the eyes, others the head, others the teeth, others the stomach and others unspecified diseases". The ancient Egyptian texts of the Old Kingdom 2635-2155 BC ; contain at least 50 physicians, mainly from their names on tombs. Surgery and mummification processes used by ancient Egyptians still amaze the modern experts. goddesses. All major and expected diseases are known and treated, ailments are attributed to spirits, ghosts and revenge by gods and Texts dealing with gynaecology cover fertility, sterility, pregnancy, contraception and abortion. Women were tested to decide whether they could conceive or not. However the Egyptians were behind Babylonian doctors who had gone further and designed the first pregnancy tests known in history. This test involved placing in the women's vagina a tampon impregnated with the juice of various plants in a solution of alum. This was left in position either overnight or for three days. Pregnancy or non-pregnancy was indicated by colour changes between red and green. The test used the pH value of the woman's secretions in. To develop an improved sense of selfcontrol when faced with stressful situations. However, studies demonstrating these strategies to be effective at reducing the core symptoms of ADHD are still required.80.

To help find a drug see Page 45 for an alphabetical listing. When a drug is available in a generic formulation, it is listed by the generic name on our formulary. 2 Drugs available for injection or infusion are typically available through specialty pharmacies, home infusion services or long term care facilities. Contact the plan for details. 3 If you are on this medication when you first enroll on our plan, there are no special coverage limitations and or prior authorizations for this medication. Please have your pharmacy contact us if you need assistance getting this medication. 4 These drugs are available at no cost to you with a prescription from your provider and are subject to usual day supply limitations. These drugs do not count towards your total out of pocket expenditure. 45.

Tolterodine cream

The update provider newsletter contains up-to-date information about Blue Cross and Blue Shield of Nebraska BCBSNE ; for healthcare providers throughout Nebraska to continually communicate with those who contract with us. If you are a BCBSNE Participating, BlueClassic and or BluePreferred healthcare provider, this newsletter serves as an amendment to your agreement with us. Therefore, it is your responsibility to comprehend and act upon all information that affects your contractual relationship with BCBSNE. You are encouraged to file every issue of the update within your BCBSNE Policies and Procedures manual. As a service for BCBS members we also send this newsletter to non-participating Nebraska providers. We also publish each issue online at: bcbsne update For permission to reprint material published in the update, e-mail the editor Marian Gramlich at: marian.gramlich bcbsne The symbols below will point you toward articles of interest as well as key contacts and information and acetazolamide. Cytochrome P450 Induction and Inhibition The ability of phenobarbital and cimetidine to induce or inhibit cytochrome P450 enzymes in canine hepatic slices was also investigated. No induction or inhibition was noted in the slices at the concentrations used in this study Tables 79 and 80 ; . In vitro induction by phenobarbital has been performed in rat liver slices. The slices were incubated for 24 hours in carbogen saturated William's Medium E containing phenobarbital 100 M based on information from prior experiments, this concentration of phenobarbital induced CYP mRNA levels and enzyme activities Lupp et al., 2001 ; . Lupp et al. 2001 ; used a semiquantitative immunohistochemistry method for staining slices to determine the location and. Positioning Novartis Pharma. to win Tougher regulatory environment More aggressive generics and bisacodyl.
Theo-Dur. Theo-Dur Sprinkles. Theolair SR. theophylline . theophylline liquid . Therapy for Acne . thiabendazole . Thiazide & Related Diuretics. thioguanine . Thioguanine, 6-TG . thioridazine . thiothixene . Third Generation Cephalosporins . Thorazine. Thyroid . Thyroid Hormones . Thyrolar . tiagabine . Tiazac . Ticlid . ticlopidine . Tigan . Tilade, nebul. soln . Timolide. timolol . timolol hemihydrate . timolol XE . timolol HCTZ . Timoptic . Timoptic-XE. Tobi . TobraDex. tobramycin . tobramycin dexamethasone . Tobrex . tocainide . Tofranil . Tofranil nonpref ; . Tofranil nonform ; . tolazamide . tolbutamide . tolcapone . Tolectin, DS . Tolinase. tolmetin . tolterodine Tonocard . Topamax . Topical Anesthetics. Topical Antibacterials . Topical Antifungals . Topical Antivirals. Topical Corticosteroids. Topical Enzymes . Topical Scabicides Pediculicides. Topicort. Topicort LP . topiramate . Toprol-XL. Toradol. toremifene . Tornalate . torsemide . T-Phyl. Tracer test strips Boehringer Mannheim ; . tramadol . Transderm-Nitro . Transderm-Sco . p. Found that the detrusor leak point pressure decreased significantly. Additionally they demonstrated the lack of severe side-effects of such therapy. b ; Cholinergics In general, bethanechol chloride seems to be of limited benefit for detrusor areflexia and for elevated residual urine volume. Elevated residual volume is often due to sphincter dyssynergia. It would be inappropriate to potentially increase detrusor pressure when concurrent DSD exists. Conclusions Bladder relaxant drugs, including oxybutynin, propiverine, trospium and tolterodine have a documented suppressive effect on incontinence by controlling overactive bladder, thereby improving storage function LOE 1 ; . However, all of these drugs presently available have considerably high incidence of side effects dry mouth, constipation, urinary retention, etc. ; , which limits their usage. Tolterodine, propiverine, trospium and controlled-release oxybutynin have significantly less side effects compared to immediate-release oxybutynin LOE 1 ; . Although the oral application is the usual way, intravesical instillation or intrarectal oxybutynin ; may be an alternative LOE 4 ; . Intravesical instillation of capsaicin resiniferatoxin has been reported to improve spinal reflex incontinence for several months after instillation presumably blocking sensory input ; . Resiniferatoxin is preferable LOE 3 ; . Botulinum toxin injections into the detrusor muscle was reported to improve incontinence and increase functional bladder capacity in spinal cord injured patients with neurologic DOA LOE 2 ; . Botulinum toxin sphincteric injections were reported to decrease outlet resistance in case of detrusor sphincter dyssynergy in patients with neurologic bladder LOE 2 ; There is no adequately designed controlled study of any drug for neurologic sphincter deficiency and leflunomide.

Tolterodine without prescription

Recordings of nerve activity in rodents indicate that circumvallate papillae are particularly sensitive to bitter compounds, while fungiform papillae are strongly biased to salty and sweet stimuli. In addition to the tongue, other parts of the oral cavity also have taste buds; these are particularly concentrated in the palate epithelium in an area known as the geschmackstreifen "taste stripe" ; . These taste buds have strong sweet responses and poor bitter sensitivity Nejad, 1986; Krimm et al., 1987 ; . If TR1 and TR2 function as specific taste receptors, we reasoned they should be expressed in subpopulations of taste receptor cells, with distinctive topographic distribution. To examine the patterns of expression of TR1 and TR2 in detail, we performed in situ hybridizations to sections of various taste papillae. Figure 4 and Table 1 illustrate the marked topographic selectivity of TR1 and TR2. TR1 is rare in the taste buds of circumvallate papillae less than 10% of circumvallate taste buds contain a TR1-positive cell ; but is expressed in all fungiform taste buds a, c, and d ; . In contrast, TR2 is almost undetectable in fungiform papillae we have observed a single positive receptor cell in over 200 fungiform taste buds. Radioligand binding in intact CHO cell monolayers. The relative selectivity for M2 and M3 mACh receptor subtypes of atropine, darifenacin, oxybutynin and tolterodine was first determined at the level of receptor binding affinity, in CHO-m2 M2 Bmax 1 pmol mg-1 protein ; or CHO-m3 M3 Bmax 1.5 pmol mg-1 protein ; cells. Saturation binding analysis yielded affinity binding constant KD ; values for [3H]-NMS at CHO-m2 and CHO-m3 cells as 0.24 0.07 and 0.37 0.07 nM, respectively data not shown ; . The affinity pKi ; and associated Hill Slopes for atropine, darifenacin, oxybutynin and tolterodine for the M2 and M3 receptor subtypes are summarized, in Table 1. Darifenacin displayed marked selectivity 14.8 fold; p 0.01 ; for the M3 over the M2 mACh receptor. In contrast, oxybutynin was nonselective, while both atropine 5.1 fold; p 0.05 ; and tolterodine 6.6 fold; p 0.05 ; displayed modest, though significant M2-selectivity Table 1 ; . Functional affinity estimates in CHO cells. Fig. 1a illustrates the protocol adopted to examine the `functional' affinity of mACh receptor antagonists at the M2 receptor, showing a representative curve for the inhibition of forskolin-stimulated cAMP accumulation by MCh in CHO-m2 cells EC50 0.27 0.03 M, n 7 ; . This allowed the estimation of an approximate EC70 concentration 1 M ; Fig. 1a ; from which antagonist inhibition curves were constructed Fig. 1b ; . pKB values were derived from these curves as described earlier see Methods ; and are summarized in Table 2 and etidronate. SECTION 8: THE INSULIN RESISTANCE SYNDROME Characterization The insulin resistance syndrome is characterized by glucose intolerance, hypertension, dyslipidemia, and visceral obesity 81, 82 ; . All of these findings are risk factors for ischemic heart disease, but insulin resistance, as assessed by the fasting insulin level, has itself been shown to be an independent risk factor for ischemic heart disease in investigations such as the Quebec Heart Study 83 ; . In fact, in that study, insulin resistance was shown to be a more important risk factor than total apolipoprotein B or HDL cholesterol levels. The dyslipidemia associated with insulin resistance is characterized by a high triglyceride level and a low HDL cholesterol level. In the atherogenicity of the dyslipidemia associated with insulin resistance, however, small dense LDL particles, postprandial hyperlipidemia, and increased remnant particles may be equally important factors 81, 84 ; . Associated Conditions Insulin resistance as a cause of hypertension is more prevalent in some ethnic minority groups than in others. The mechanism for the increased prevalence of hypertension is related to higher insulin levels acting on the renal tubule, increased reabsorption of sodium, and vasoconstriction through stimulation of the sympathetic system by insulin 85 ; . In addition, the insulin resistance syndrome is associated with endothelial dysfunction 82, 86 ; , leading to a decrease in production of nitric oxide. The decreased production of nitric oxide, in turn, leads to vasoconstriction and stimulation of clotting factors, platelet aggregation, and decreased breakdown of fibrinogen through stimulation of plasminogen activator inhibitor. Endothelial dysfunction is also associated with increased endothelial permeability to molecules such as lipoproteins. In addition, activation of growth factors leads to accelerated atherosclerosis. Abnormal endothelial permeability is also present in the glomerulus, in reality an arteriole, leading to microalbuminuria and proteinuria. The level of proteinuria has been shown to be inversely proportional to the insulin sensitivity. In patients who are at high risk for diabetes because of insulin resistance, proteinuria will often be detected before fasting or postprandial blood glucose levels are found to be high. Overt diabetes will develop when insulin production cannot be increased to overcome insulin resistance. In comparison with thin patients, many obese patients without diabetes produce 5 to 8 times more insulin--an amount that can be as much as 500 U day--to overcome insulin resistance. Thus, type 2 diabetes can be attributed to a genetic failure of the pancreatic beta cells to compensate for insulin resistance 87 ; . The presence of hyperuricemia, with or without clinical manifestations of gout, is also a feature of the metabolic syndrome which includes insulin resistance. Therefore, patients known to have hypertension, dyslipidemia, hyperuricemia, or gout at an!
1. Dr. M. Yassini MD 2. Dr. Z. Pourmovahed MS 1-2: Department of General Psychiatry, Shahid Sadoughi University of Medical Sciences, Yazd, IRAN. Correspondences: Dr. M. Yassini, Shahid Sadoughi Medical Sciences University Deputy for Research, Building No.2, Bahonar Square, P.O. Box: 734, Yazd IRAN. E-Mail: yassini ssu.ac.ir and raloxifene. Espy PG, Wind A, Wade B, et al. Long-term trends following subcapsular prostatectomy for benign prostatic hyperplasia [abstract 1498]. J Urol. 2007; 177 4 suppl ; : 494. Helfand BT, Vyas A, Fine M, et al. Post-operative PSA values and PSA velocity predict the presence of prostate cancer following various surgical interventions for benign prostatic hyperplasia BPH ; [abstract 1503]. J Urol. 2007; 177 4 suppl ; : 496. Armitage J, Sibanda N, Cathcart P, et al. Acute urinary retention is associated with an increased risk of mortality [abstract 1507]. J Urol. 2007; 177 4 suppl ; : 497. Nickel JC, Roehrborn CG, O'Leary MP, et al. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial [abstract 98]. J Urol. 2007; 177 4 suppl ; : 34-35. Roehrborn CG, Marberger M, Tubaro A, et al. Relationship between screening IPSS and the placebo run-in response in the pooled REDUCE and COMBAT population [abstract 1557]. J Urol. 2007; 177 4 suppl ; : 514-515. Barkin J, Guimares M, Jacobi G, et al. Alphablocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride. Eur Urol. 2003; 44 4 ; : 461-466. Barkin J, Koch C, Dupont C, et al. Finasteride monotherapy maintains stable urinary symptoms IPSS ; in men with benign prostatic hyperplasia for 9 months after 9 months of combination therapy using both an alpha-blocker and finasteride [abstract 1561]. J Urol. 2007; 177 4 suppl ; : 516. Johnson TM, Burros PK, Kusek JW, et al. The effect of doxazosin, finasteride, and combination therapy on nocturia in men with benign prostatic hyperplasia [abstract 1549]. J Urol. 2007; 177 4 suppl ; : 511. Roehrborn CG, McVary KT, Kaminetsky JC, et al. The efficacy and safety of tadalafil administered once a day for lower urinary tract symptoms LUTS ; in men with benign prostatic hyperplasia BPH ; [abstract 1636]. J Urol. 2006; 175 4 suppl ; : 527. McVary KT, Swierzewski MJ, Monnig WB, et al. Sildenafil improves erectile function and concomitant lower urinary tract symptoms in men [abstract 920]. J Urol. 2006; 175 4 suppl ; : 298. Kaplan SA, Gonzalez RR, Ogiste J, et al. Combination of an alpha blocker, alfuzosin SR and a PDE-5 inhibitor, sildenafil citrate is superior to monotherapy in treating lower urinary tract symptoms LUTS ; and sexual dysfunction [abstract 1638]. J Urol. 2006; 175 4 suppl ; : 528. Stief CG, Porst H, Evers T, Ulbrich E. Varedenafil in the treatment of symptomatic benign prostatic hyperplasia [abstract 1565]. J Urol. 2007; 177 4 suppl ; : 517. Debruyne FMJ. The efficacy and safety of ozarelix, a novel GNRH antagonist, in men with lower urinary tract symptoms LUTS ; due to benign prostatic hyperplasia BPH ; [abstract 1552]. J Urol. 2007; 177 4 suppl ; : 512. Kaplan SA, Rovner ES, Sussman DO, et al. Effects of tolterodine extended release and or tamsu.
Tobramycin NEBCIN Tobramycin TOBREX Tobramycin + Dexamethasone TOBRADEX Tobramycin, solution for inhalation TOBI Tocainide TONOCARD Tolazamide TOLINASE Tolbutamide ORINASE Tolcapone TASMAR Tolmetin TOLECTIN Tolnaftate TINACTIN Tlterodine . TROL Tolterodine, extended-release TROL LA Topiramate TOPAMAX Toremifene FARESTON Torsemide . MADEX Tramadol ULTRAM Tramadol + Acetaminophen ULTRACET Trandolapril MAVIK Trandolapril + Verapamil TARKA Tranylcypromine PARNATE Trastuzumab HERCEPTIN Travoprost TRAVATAN Trazodone . SYREL Treprostinil REMODULINTM Tretinoin . Tretinoin RENOVA Tretinoin RETIN-A Triamcinolone ARISTOCORT Triamcinolone AZMACORT Triamcinolone KENALOG Triamcinolone NASACORT Triamcinolone TRI-NASAL Triamcinolone ARISTOCORT A Triamcinolone Diacetate, injection ARISTOCORT FORTE Triamcinolone Hexacetonide, injection ARISTOSPAN Triamterene DYRENIUM Triamterene + Hydrochlorothiazide DYAZIDE Triamterene + Hydrochlorothiazide MAXZIDE Triazolam HALCION Triethanolamine CERUMENEX Trifluoperazine . ELAZINE Trifluridine VIROPTIC Trihexyphenidyl ARTANE Trimethadione TRIDIONE and alendronate. 50% higher, respectively, than reported in young healthy volunteers. However, no overall differences were observed in safety between older and younger patients on tolterodine in the Phase 3, 12-week, controlled clinical studies; therefore, no tolterodine dosage adjustment for elderly patients is recommended see PRECAUTIONS, Geriatric Use ; . Pediatric: Efficacy in the pediatric population has not been demonstrated. The pharmacokinetics of tolterodine extended release capsules have been evaluated in pediatric patients ranging in age from 11-15 years. The dose-plasma concentration relationship was linear over the range of doses assessed. Parent metabolite ratios differed according to CYP2D6 metabolizer status: EMs had low serum concentrations of tolterodine and high concentrations of the active 5-hydroxymethyl metabolite, while PMs had high concentrations of tolterodine and negligible active metabolite concentrations. Gender: The pharmacokinetics of tolterodine immediate release and the 5-hydroxymethyl metabolite are not influenced by gender. Mean Cmax of tolterodine immediate release 1.6 g L in males versus 2.2 g L in females ; and the active 5hydroxymethyl metabolite 2.2 g L in males versus 2.5 g L in females ; are similar in males and females who were administered tolterodine immediate release 2 mg. Mean AUC values of tolterodine 6.7 gh L in males versus 7.8 gh L in females ; and the 5hydroxymethyl metabolite 10 gh L males versus 11 gh L females ; are also similar. The elimination half-life of tolterodine immediate release for both males and females is 2.4 hours, and the half-life of the 5-hydroxymethyl metabolite is 3.0 hours in females and 3.3 hours in males. Race: Pharmacokinetic differences due to race have not been established. Renal Insufficiency: Renal impairment can significantly alter the disposition of tolterodine immediate release and its metabolites. In a study conducted in patients with.

Tolterodine classification

Ence of 30 and 300 nM tolterodine are shown in Fig. 4A. Under these conditions tolterodine inhibited Ca2 channel currents with an IC50 value of 143 nM 98 208 nM, 95% CL; Fig. 4B ; . We also examined the effects of tolterodine on Ca2 channels stimulated at a constant frequency of 0.1 Hz. At this frequency the drug was less potent displaying an IC50 value of 1084 nM 818 1437 nM, 95% CL; Fig. 4B ; . To further examine this frequency dependence, we stimulated cells in absence of drug for 3 min at a rate of either 0.1 or 1 Hz Fig. 4, C and D, respectively ; . After this, cells were allowed to equilibrate with 300 nM tolterodine for 3 min without pulsing. After this equilibration period, the pulse trains were repeated. Topterodine was more effective at blocking Ca2 currents at 1 Hz compared with 0.1 Hz. When cells were stimulated at 0.1 Hz, Ca2 current decreased by 4 2% in the absence of drug and by 24 6% in the presence of 300 nM tolterodine Fig. 3C ; . At 1-Hz stimulation frequency, Ca2 current declined by 20 3% under drug-free conditions and by 60 6% in the presence of tolterodine Fig. 3D ; . It seems that the drug block observed in Fig. 3, C and D, did not reach a complete steady state. Therefore, the IC50 values reported in Fig. 3B may underestimate, to some degree, the true affinity of tolterodine for cardiac Ca2 channels, especially at the 1-Hz stimulation rate. We next examined the effects of tolterodine on action potentials recorded from guinea pig ventricular myocytes and compared these effects to those observed for dofetilide. Figure 5A shows the effects of tolterodine 3100 nM ; on the action potential waveform. Figure 5B illustrates the effects of dofetilide 3100 nM ; on the action potential waveform. Both drugs increased action potential duration in a dose-dependent manner, but the effects of dofetilide were more pronounced. APD90 was increased by 4 1, 8 and 28 6% in the presence of 3, 10, 30, and 100 nM tolterodine, respectively. These same concentrations of dofetilide prolonged APD90 by 8 1, 30 and 65 17 and calcitriol. 285 Liu C, Andrews GR. Prevalence and incidence of urinary incontinence in the elderly: a longitudinal study in South Australia. Chinese Medical Journal 2002; 115: 11922. Herzog AR, Fultz N, Brock BM, Brown MB, Diokno AC. Urinary incontinence and psychological distress among older adults. Psychology and Aging 1988; 3: 11521. Szonyi G, Collas DM, Ding YY, Malonelee JG. Oxybutynin with bladder retraining for detrusor instability in elderly people a randomized controlled trial. Age and Ageing 1995; 24: 28791. Ouslander JG, Schnelle JF, Uman G, Fingold S, Nigam JG, Tuico E, Jensen BB. Does oxybutynin add to the effectiveness of prompted voiding for urinary incontinence among nursing-home residents a placebo controlled trial. J Geriatr Soc 1995; 43: 6107. Jarvis GJ. A controlled trial of bladder drill and drug-therapy in the management of detrusor instability. Br J Urol 1981; 53: 5656. Madersbacher H, Halaska M, Voigt R, Alloussi S, Hofner K. A placebo controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU Int 1999; 84: 64651. Thuroff JW, Bunke B, Ebner A, Faber P, Degeeter P, Hannappel J et al. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity oxybutynin versus propantheline versus placebo. J Urol 1991; 145: 8137. Moore KH, Hay DM, Imrie AE, Watson A, Goldstein M. Oxybutynin hydrochloride 3 mg ; in the treatment of women with idiopathic detrusor instability. Br J Urol 1990; 66: 47985. Tapp AJS, Cardozo LD, Versi E, Cooper D. The treatment of detrusor instability in postmenopausal women with oxybutynin chloride a double-blind placebo-controlled study. Br J Obstet Gynaecol 1990; 97: 5216. Zorzitto ml, Holliday PJ, Jewett MAS, Herschorn S, Fernie GR. Oxybutynin chloride for geriatric urinary dysfunction a double-blind placebo-controlled study. Age and Ageing 1989; 18: 195200. Anderson RU, Mobley D, Blank B, Saltzstein D, Susset J, Brown JS. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. J Urol 1999; 161: 180912. Millard R, Tuttle J, Moore K, Susset J, Clarke B, Dwyer P et al. Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. J Urol 1999; 161: 15515. Larsson G, Hallen B, Nilvebrant L. Tolterodone in the treatment of overactive bladder: analysis of the pooled phase II efficacy and safety data. Urology 1999; 53: 9908. Abrams P, Freeman R, Anderstrom C, Mattiasson A. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 1998; 81: 80110. Appell RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: A pooled analysis. Urology 1997; 50: 906. Van Kerrebroeck P, Kreder K, Jonas U, Zinner N, Wein AN. Tolterodibe once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001; 57: 41421.
KIDNEY TRANSPLANTATION Trends in Induction Therapy in Kidney Transplantation Induction therapy refers to the temporary use of high doses of immunosuppressive medications in the early post-transplant period. Recipients treated with induction immunosuppression typically receive a brief course of antibody therapy that is intended to reduce or modify early immune system activity against the transplanted and risedronate. Immature microvessels, which might play a role in glomerulation. Abnormal Urine Protein May Be Key to Bladder Damage in IC Sialic acid content of urinary Tamm-Horsfall protein is reduced in interstitial cystitis patients C. Lowell Parsons, Mahadevan Rajasekaran, Marianne Chenoweth, Paul Stein, San Diego, CA Tamm-Horsfall protein is thought to neutralize chemicals in urine that can damage bladder lining, but IC patients apparently don't make a normal version of this protein, so this may be a reason that IC bladders sustain damage. The difference seems to be in the sialic acid content of the protein, which makes the protein electrochemically abnormal and prevents it from neutralizing positively charged, damaging chemicals. To test that idea, the investigators compared the sialic acid content and electrostatic potential if the protein from 28 IC patients and 29 healthy controls. The Tamm-Horsfall protein from IC patients did, indeed, have a lower sialic acid content and a lower electrostatic potential than controls. There was no difference, however, between the quantity of TammHorsfall protein in urine between the IC patients and controls. This research might help us understand the cause of IC, concluded the investigators. More Evidence that IC Bladder Cells are Different from Normal Cells Increased efficacy and potency of carbachol in inducing increases in intracellular calcium [Ca2 + ]i ; and outward potassium currents I0 ; in interstitial cystitis IC ; bladder urothelial cells BUC ; : Evidence of persistent phenotypic alteration of cultured human IC BUC Gopal N Gupta, Mingkai Li, Yan Sun, Michael Gold, Marc Simard, Toby C Chai, Baltimore, MD Basic research on bladder lining cells in IC has already shown that they may release neurotransmitters and produce APF, unlike normal cells. To find more differences, these researchers used electrophysiologic measurements and techniques that measure calcium ions. Calcium ions play a role in transmitting nerve signals. ; The researchers added a stimulator called carbachol to the cells and found that IC cells reacted very differently from normal cells. IC cells had much greater electrical activity and more calcium ions. Taking away calcium from the cells' environment and adding the drug tolterodine Detrol ; , an overactive bladder drug, erased the differences. Based on these results, this research team concurs that bladder lining cells play a central role in the IC disease process. Nerve Stimulation, Not Anticipation, Affects Sensation, Pain Brain Areas. Vesicare achieved the primary objective of non-inferiority vs. tolterodine ER in change in micturition frequency Solifenacine is superior to tolterodine ER in urgency episodes, incontinence, urge incontinence Toltefodine ER Superior Vesicare tolterodine ER Equivalence Frequency p 0.0681 ; Nocturia P 0.7298 ; Vesicare Superior Urgency Episodes P 0.0353 ; Incontinence P 0.0059 ; Urge Incontinence P 0.001 ; 50% Reduction Incontinence Episodes P 0.0212 ; Dry rate P 0.0059 ; Number of Pads Used Source : XXth EAU, Satellite symposium "Refinding best practice in OAB" Mar 17, 2005, Istanbul, Turkey P 0.0023 ; Volume Voided P 0.0103 ; 13 and flutamide and Buy tolterodine online. Biofeedback therapy is useful in the management of OAB primarily by reducing the outlet resistance during voiding that leads to detrusor hypertrophy, thereby leading to detrusor instability. Our data [25] along with more recent work [26], reveals that biofeedback therapy is useful in the elimination of reflux in children that exhibit evidence of external sphincter dyssynergia. Drug therapy of overactive bladder syndrome Anticholinergics Many classes of drugs have been studied or proposed for the treatment of symptoms of OAB in adults. A total of five antimuscarinics are currently approved in the USA for the treatment of OAB: darifenacin, oxybutynin, solifenacin, tolterodine and trospium a sixth, propiverine, is available in Europe ; . Studies of these agents have demonstrated similar efficacy 7075% ; for decreasing urge incontinence episodes. As of today, only two antimuscarinics have formally achieved approval for use in children oxybutynin and tolterodine ; and one is in the process of obtaining approval. Several pitfalls limit the quality of clinical studies, heterogeneity of the patients and their symptoms and the fact that many patients can have more than one confounding problem. The clinical trials performed in children have generally utilized patients with neurogenic voiding problems and have not concentrated on the non neurogenic patients. Recent data suggests that antimuscarinics are functioning on the sensory limb of the reflex arc in neurologically intact patients, more so than at the motor side [27]. Antimuscarinics are active during the filling storage phase of micturition when there is no activity in the cholinergic nerves. Acetylcholine can be generated and released from the urothelium and also may `leak' from the cholinergic nerves during bladder filling [14], binding to M2 and M3 receptors. There are five subtypes of muscarinic receptors that are recognized and the bladder smooth muscle has two known subtypes M2 7080% ; and M3 2030% ; that predominate. M3 receptors have been demonstrated to evoke smooth muscle contraction, which is the primary stimulus for bladder contraction. It has been postulated that M2 and M3 receptors are involved not only in motor efferent ; activation, but also in sensory afferent ; activation as well. The activation of M2 receptors may reverse sympathetically mediated smooth muscle relaxation during the filling storage phase. Herba Andrographidis should not be used during pregnancy or lactation. Herba Andrographidis is contraindicated in cases of known allergy to plants of the Acanthaceae family and finasteride. 1. Hegde SS. Muscarinic receptors in the bladder: from basic research to therapeutics. Br J Pharmacol. 2006; 147 suppl 2 ; : S80S87. 2. Brunton S, Kuritzky L. Recent developments in the management of overactive bladder: focus on the efficacy and tolerability of once daily solifenacin succinate 5 mg. Curr Med Res Opin. 2005; 21 1 ; : 7180. 3. Chapple CR, Cardozo L, Steers WD, Govier FE. Solifenacin significantly improves all symptoms of overactive bladder syndrome. Int J Clin Pract. 2006; 60 8 ; : 959966. 4. Staskin D, Dmochowski R, Serels S, Andoh M, Hussain I, Smith N. Report from a randomized, placebo-controlled study showing significant improvement in urgency and patient-reported outcomes in overactive bladder patients treated with solifenacin. Int Urogynecol J. 2007; 18 suppl 1 ; : S73. 5. Chapple CR, Martinez-Garcia R, Selvaggi L, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol. 2005; 48 3 ; : 464470. 6. Wagg A, Wyndaele JJ, Sieber P. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: A pooled analysis. J Geriatr Pharmacother. 2006; 4 1 ; : 1424. 7. Staskin DR, MacDiarmid SA. Pharmacologic management of overactive bladder: practical options for the primary care physician. J Med. Mar 2006; 119 3 suppl 1 ; : 2428. 8. Haab F, Cardozo L, Chapple C, Ridder AM. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol. 2005; 47 3 ; : 376384. 9. Chapple CR, Arano P, Bosch JL, De Ridder D, Kramer AE, Ridder AM. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodinecontrolled phase 2 dose-finding study. BJU Int. 2004; 93 1 ; : 7177. 10. VESIcare [package insert]. Deerfield, IL: Astellas Pharma, US, Inc.; 2005. 11. Smulders RA, Kuipers ME, Krauwinkel WJ. Multiple doses of the antimuscarinic agent solifenacin do not affect the pharmacodynamics or pharmacokinetics of warfarin or the steady-state pharmacokinetics of digoxin in healthy subjects. Br J Clin Pharmacol. 2006; 62 2 ; : 210217. 12. Taekema-Roelvink ME, Swart PJ, Kuipers ME, Krauwinkel WJ, Visser N, Smulders RA. Pharmacokinetic interaction of solifenacin with an oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women: a double-blind, placebo-controlled study. Clin Ther. 2005; 27 9 ; : 14031410. 13. Krauwinkel WJ, Smulders RA, Mulder H, Swart PJ, Taekema-Roelvink ME. Effect of age on the pharmacokinetics of solifenacin in men and women. Int J Clin Pharmacol Ther. 2005; 43 5 ; : 227238. 14. Andersson KE. Antimuscarinics for treatment of overactive bladder. Lancet Neurol. 2004; 3 1 ; : 4653. 15. Kuipers M, Smulders R, Krauwinkel W, Hoon T. Open-label study of the safety and pharmacokinetics of solifenacin in subjects with hepatic impairment. J Pharmacol Sci. 2006; 102 4 ; : 405412. 16. Astellas Pharma US, Inc. Astellas Worldwide Market Authorization Status. June 2007. 17. Astellas Pharma US, Inc. Astellas internal data, IMS MIDAS Global Sales Audit, IMS NPA, SDI Surveillance Data Inc. ; patient longitudinal data, from August 2004 to March 2007. 18. Dresser GK, Bailey DG. A basic conceptual and practical overview of interactions with highly prescribed drugs. Can J Clin Pharmacol. Winter 2002; 9 4 ; : 19911998. Group. The comparative tolerability and efficacy of tolterodine 2 mg bid versus oxybutynin 2.5 5 mg bid in the treatment of the overactive bladder. Proc ICS. 1998; 220: 163-164. O'Conor RM, Johannesson M, Hass SL, KobeltNguyen G. Urge incontinence: quality of life and patient's valuation of symptom reduction. Pharmacoeconomics. 1998; 14: 531-539. Goldstein M, Hawthorne ME, Engeberg S, McDowell BJ, Burgio KL. Urinary incontinence: why people do not seek help. J Gerontol Nurs. 1992; 18: 15-20. Chancellor M, Freedman S, Mitcheson HD, et al. Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms. Clin Drug Invest. 2000; 19: 83-91. Van Kerrebroeck P, Kreder K, Jonas U, Zinner N, Wein A. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology. 2001; 57: 414-421. Pleil AM, Reese PR, Kelleher CJ, Okano GJ. Health related quality of life of patients with overactive bladder receiving immediate release tolterodine. Health Econ Prev Care. 2001; 2: 69-75. Conway K, Uzun V, Marrel A, et al. Linguistic validation of the King's Health Questionnaire KHQ ; in eight languages [abstract]. Value Health. 1999; 2: 204. Ware JE, Kosinski M, Keller SD. SF-36 Physical & Mental Health Summary Scales: A User's Manual. Boston, Mass: Health Assessment Lab, New England Medical Center Institute; 1994. 18. Aaronson NK, Acquadro C, Alonso J, et al. International Quality of Life Assessment IQOLA ; Project. Qual Life Res. 1992; 1: 349-351. Kelleher CJ. Quality of life. In: Cardozo L, editor. Urogynecology: The King's Approach. Edinburgh, United Kingdom: Churchill Livingstone; 1997: 673-688. 20. Sankoh AJ, Huque MF, Dubey SD. Some comments on frequently used multiple endpoint adjustment methods in clinical trials. Stat Med. 1997; 16: 2529-2542. Pleil AM, Reese PR, Okano GJ, Kelleher CJ. Validation of King's Health Questionnaire in patients with symptoms of overactive bladder. Qual Life Res. 2000; 9: 347. Meyhoff HH, Gerstenberg TC, Nordling J. Placebo--the drug of choice in female motor urge incontinence? Br J Urol. 1983; 55: 34-37. Abrams P, Larsson G, Chapple C, Wein AJ. Factors involved in the success of antimuscarinic treatment. BJU Int. 1999; 83 suppl 2 ; : 42-47. The Dementia Epidemic: Economic Impact and Positive Solutions for Australia provide flexibility of care routines and practices a relaxed organisational environment using strategies that focus on timing, routines and needs of residents, preventing resistive responses; 25 cultivate professionalism of care and support of staff create a culture of doing something innovative, progressive and worthwhile, rather than a task-oriented `completion of jobs' approach; include relatives in the life and care of the resident expend effort to maintain continuity in the resident's life through encouraging ongoing contact with family and others who can provide undivided personal attention. Person-centred care philosophy Care is about the person behind the illness, and entering into their world. A fundamental premise is that all people are entitled to the best possible quality of life, with dignity, in comfortable surroundings and with the assurance that he or she has personal worth and is valued by others. `Challenging' reactions and behaviours may be environmentally provoked and are rarer in a calm environment with trained staff who are understanding and take a personal interest in the residents and who promote a feeling of security. Sherman 1999 ; is an excellent book for carers, written from many years' experience as an Australian carer in a residential setting and also caring for her husband, Bill, who had dementia. The book is rich with personalised examples of care that is full of skilled insights into the reasons for behaviours, patience, respect, wisdom and humane strategies for sensitively helping people. For example, people with dementia may be prone to agitation, wandering, suspiciousness, inappropriate language or screaming, sexual disinhibition, apathy, self-injury, combativeness, repetitious demands or resistance to maintaining hygiene. In each case there is a need to seek the reason underlying the specific behaviour, and then as far as possible to meet the need - listening, responding, gently prompting, providing reassurance, company, respect, praise, etc. The following checks can also help: environmental modifications, such as limiting noise and glare from windows to reduce confusion caused by over-stimulation, putting calendars and clocks in many rooms, or playing soft music providing predictable but stimulating routines with structured times for daily activities and, if insomnia is a problem, cutting down caffeine, getting regular exercise and avoiding daytime naps explaining tasks beforehand, for example "Peter, I'm going to help you put on your shirt now" providing reassurance without challenging or contradicting accusations or misperceptions redirecting attention and use of light-heartedness and humour "The man in the mirror is taking his clothes off you put yours on and he'll put his back on too!" dignified precautions to help prevent wandering intrusions "attacks" eg, disguised doors, signs recording behaviour patterns including frequency, timing and strategies that work with that person. Modelling: The three women who sit near the outside door are irritated by Bob, who no longer knows, and is beyond learning, how to manipulate handles and knobs. Several times a day he tries to go into the garden. Gripping the handle, he rattles the door. The women call to him to stop. `Go away, go away' they tell him, as he becomes infuriated when the door fails to open. For the next day of two the nurse quietly opens the door for him. `There you are, Bob, you can go out now', each time turning to the women to say, `He has forgotten how to open the door. He can't help it, you know.' From then on, one or other of the women opens the door for Bob, explaining to anyone who cares to listen, `He can't help it, he's forgotten.' Staff praise them for their caring attitude. Sherman 1999.
Nearly 40, 000 older adults were injured on escalators during the time period, according to data from the U.S. Consumer Product Safety Commission. The average age of the injured was 80, and three out of four of the injured were women. Slips, trips and falls were the most common accidents and most of the time resulted only in bruises. The risk of escalator mishaps among the elderly is about The study, by Dr Kaycee Sink of Wake eight injuries per 100, 000 people. Although most accidents weren't serious, about Forest University School of Medicine 3, 000 people were taken to the emergency room. in North Carolina, looked at residents of nursing homes, where the two most Notably, many of the accidents were the result of careless behavior by elderly common medical conditions, dementia escalator riders. One older rider fell because he tried to squeeze past a wheelchair user and an attendant, who shouldn't have been using the escalator in the first and urinary incontinence, are often place. present in the same patient. Of the residents studied, about 10% of those "What really surprised us was the reckless behavior exhibited by some older adults on escalators, " said study coaubeing being treated with cholesterinase thor Greg Steele, associate professor of inhibitors for dementia were also takepidemiology. "Obviously, the wheeling either Pfizer's Detrol tolterodine ; chair should not have been on the moving or Ortho-McNeil's Ditropan oxybustairs. And of course the injured individutynin ; , both anticholinergics and the al should not have attempted to beat them two most commonly prescribed treatdown the stairs." ments for urinary incontinence. Older adults who have difficulty walking or maintaining balance should use It is likely that the oppositional effects elevators rather than escalators, the study of the drugs contributed to the accelauthors caution. And when elderly people do ride escalators, they should use erated decline in these patients, said extra care when stepping on or off the moving steps. Dr Sink, who described the findings, published on-line by the Journal of the "They should not try to walk up or down a moving escalator, carry large objects, American Geriatrics Society, as repre- or wear loose shoes or clothing while riding, since these appear to be associated with an increased risk of falling, " said coauthor Dr. Joseph O'Neil, associate senting a major public health problem. professor of clinical pediatrics. Dr. O'Neil said injury should be viewed as a "medical illness" alongside heart The results of another study by Dr disease, diabetes and stroke. Sink, presented earlier this month "We have to stop thinking of unexpected injuries as accidents, which implies that at the American Geriatrics Society they are unpreventable, '' Dr. O'Neil said. "Escalator injuries, like auto crashes Meeting in Washington, showed that and many other so-called accidents, can be prevented." patients being treated with anticho .NY Times. 1. 2. 3. Nilvebrant L, Andersson K-E, Gillberg P-G, et al. Tolterodine - a new bladder-selective antimuscarinic agent. Eur J Pharmacol 1997; 327: 195-207 Appell RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology 1997; 50 suppl 6A ; : 90-6 Jonas U, Hfner K, Madersbacher M, et al. Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. World J Urol 1997; 15; 144-51 Abrams P, Freeman RN, Anderstrm C, Mattiasson A. Efficacy and tolerability of tolterodine vs. oxybutynin and placebo in patients with detrusor instability. J Urol 1996; 157 suppl ; : 103 abstr 402 Van Kerrebroeck PhEVA, Serment G, Dreher E. Clinical efficacy and safety of tolterodine compared to oxybutynin in patients with overactive bladder. abstr ; Neurourol Urodyn 1997; 16: 478-9 Drutz H, Appell RA. Clinical efficacy and safety of tolterodine vs. oxybutynin and placebo in patients with unstable bladder. Abstract from: 15th FIGO World congress of gynecology and obstetrics. Copenhagen August 3-8 1997 Malone-Lee JG et al The comparative tolerability and efficacy of tolterodine 2mg bid versus oxybutynin 2.5 5mg bid in the treatment of the overactive bladder. Conference of the International Continence Society Cambridge UK 2-3rd April 1998 Fantl JA, Newman DK, Colling J, et al. Urinary Incontinence in Adults: Acute and Chronic Management. Clinical Practice Guideline No. 2, 1996 Update. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service, Agency for Health Care Policy and Research. AHCPR Publication No. 96-0682. March 1996 British National Formulary, Number 34. London: British Medical Association and Royal Pharmaceutical Society of Great Britain. 1997 Detrusitol. Summary of Product Characteristics Pharmacia & Upjohn Dec 1997 Halln B, Nordgren L, Landelius J, et al. Tolterodine and terodiline ECG safety profiles. 27th annual meeting of the International Continence Society 1997; 143-4 and buy acetazolamide. In nearest integer. Post-marketing Surveillance The following events have been reported in worldwide post-marketing experience: General: angioedema; Cardiovascular: tachycardia, Gastrointestinal: diarrhea; Central Peripheral memory impairment, hallucinations. association with tolterodine use in anaphylactoid reactions, including palpitations, peripheral edema; Nervous: confusion, disorientation. Exercise it at times when you are not urinating. These exercises can be done anywhere and at any time and in various positions such as lying down, sitting, or standing. For maximum benefit, three sets of these exercises should be done over the course of the day. During each set, 25 repetitions should be performed. For 5 seconds, if possible, this muscle should be contracted, and then for 5 seconds relaxed. After completion of 25 repetitions of alternating "squeeze, relax" etc., the set is completed. Gradually, the strength and tone of the pelvic floor muscles will increase. Please attend closely to those activities and events that previously have resulted in triggering the LUTS. By actively squeezing the pelvic floor muscles just before and during these activities, the LUTS can often be improved. There are a variety of bladder relaxant medications that are useful to suppress bladder overactivity. It may take several trials of different medications or combinations of medications to achieve optimal results. The newest medications are Detrol LA Tolterodine ; , Ditropan XL Oxybutynin ; , Oxytrol trans-dermal oxybutynin ; , Sanctura Trospium ; , Enablex Darifenacin ; and Vesicare Solifenacin ; are effective and have the least amount of side effects. The most common side effect of all the bladder relaxant medications is dryness that can involve any moist body area, particularly the mouth. These medications cannot be used in the presence of urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma. Oxybutynin is now available in trans-dermal skin patch ; form known as Oxytrol.

Tolterodine spc

Food-maintained responding; however, the suppression of cocaine self-administration is greater than the reduction in food-maintained responding. Our results with PAL-287 confirm the hypothesis that a non-amphetamine substrate at DAT and SERT will release DA and 5-HT from neurons in vivo, be minimally reinforcing, and suppress ongoing cocaine self-administration. PAL-287 displays several desirable qualities for a candidate treatment medication, including minimal locomotor activation, lack of long-term 5-HT neurotoxicity, and low abuse potential. Future studies will be necessary to determine the potential of PAL-287 for increasing the risk for PPH, perhaps by determining its potency at human voltage-gated K + channels.82 The present data with PAL-287 support the use of monoamine releasers as agonist medications for the treatment of stimulant addictions. A dose of 1.0 mg kg hr PAL-287 virtually eliminated cocaine self-administration in rhesus monkeys by the end of the 7-day treatment, although this effect was not entirely selective for cocaine vs food. E7.

Tolterodine spc

Kaplan SA: The 12 year outcome analysis of an endourethral Wallstent for treating benign prostatic hyperplasia. J Urol, 174 4 ; : 1354 1355, 2005. Kaplan SA: Three dimensional ultrasonography in evaluation of benign prostatic hyperplasia. J Urol, 174: 1904, 2005. Kaplan SA: Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. J Urol, 174: 1905, 2005. Kaplan SA: Patients with a large prostate show a higher prevalence of androgenic alopecia. J Urol, 174 5 ; : 1905, 2005. Kaplan SA: Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase 2, Bcl 2, and cell proliferation in the glandular epithelium. J Urol, 174: 2281, 2005. Kaplan SA: Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5 reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia. J Urol, 174: 2282, 2005. Kaplan SA: A comparison of four different 1 blockers in benign prostate hyperplasia patients with and without diabetes. J Urol, 174: 2282 2283, Kaplan SA, Walmsley K and Te AE: Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol, 174 6 ; : 2273 2276, 2005. Capodice JL, Bemis DL, Buttyan R, Kaplan SA, Katz AE: A literature review of complementary and alternative medicine for chronic prostatitis chronic pelvic pain syndrome. Evidence based complementary and alternative medicine. : ecam.oxfordjournals . October, 2005. Kaplan SA, DeRose AF, Kirby RS, O'Leary MP, McVary KT: Beneficial effects of extendedrelease doxazosin and doxazosin standard on sexual health. BJU International. BJU Int. 97 3 ; : 559-66, 2006. Giulliano F, Kaplan SA, Cabanis MJ: Hemodynamic interaction study between the alpha1blocker alfuzosin and the phosphodiesterase 5 inhibitor tadalafil in middle-aged healthy male subjects. Urology, 67: 1199 1204, Kaplan SA, Roehrborn CG, Dmochowski R, Rovner ES, Wang JT, Guan Z: Tolterodine extended release improves overactive bladder symptoms in continent men with overactive bladder and nocturia. Urology, 68: 328 332, Kaplan SA: Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer. J Urol, 175 3 ; : 1032 1033, 2006. Kaplan SA: Expression of cyclooxygenase 1 and cyclooxygenase 2 in the human prostate. J Urol, 175 3 ; : 1033, 2006. 27. Generic Name Tolterodine Medication Brand Name Detrol Ditropan Tertiary Amines Oxybutynin OxytrolTM Enablex Vesicare Route Oral Oral Transdermal Oral Oral Oral Oral Active M Receptor Metabolism Compound Selectivity in Urine Nonselective M3 Selective M3 Selective M3 Selective Nonselective Nonselective Hepatic 15% Other Characteristics Bladder selectivity higher selectivity for the bladder than for the salivary glands, which may reduce dry mouth ; . May be less effective in poor metabolizers. * Highest risk of CNS side effects. Hepatic 1% Lowest rate of dry mouth and constipation. May cause skin irritation at patch site. Highest rate of constipation. No QT interval prolongation. Bladder selectivity higher selectivity for the bladder than for the salivary glands, which may reduce dry mouth ; . Requires frequent dosing because of its short half life. Lowest risk of CNS side effects. Highest excretion of active compound in the urine. No QT interval prolongation.
Tolterodine pharmacodynamics

Star solifenacin tolterodine

Tolterodinne, toterodine, tolteroddine, tolterodone, tooterodine, tolterodune, tloterodine, topterodine, tolterod9ne, tollterodine, tolteroine, tolherodine, tolter9dine, tolterdine, golterodine, tolte4odine, holterodine, olterodine, yolterodine, t9lterodine, tolyerodine, tolter0dine, tolterodibe, toltrodine, tolte5odine, toletrodine, tolterodihe, tol5erodine, tolteroeine, tlterodine, tolterodind, tolterocine, tolterodiine, tolterod8ne, toltreodine, tolterldine, tolterodkne, tolterodije, tolterodjne, tolterorine, toltwrodine, tolterofine, toltetodine, tolterodnie, tolteeodine, tolferodine, 6olterodine, tolterdoine, tolteroxine.

Tolterodine cream, tolterodine without prescription, tolterodine classification, tolterodine spc and tolterodine pharmacodynamics. Star solifenacin tolterodine, tolterodine and memory loss, buy tolterodine online and darifenacin and tolterodine or tolterodine la.

Tolterodine and memory loss

Nasogastric equipment, smith beecham klein, somatotropin wholesale, hyper 45 and acarbose vs gliclazide. Shoulder 17, what is dyazide use for, remicade opinions and plasma donation ny or pathophysiology of kawasaki disease illness.

 
© 2005-2009 Usa-now.free0host.com, Inc. All rights reserved.
Free Web Hosting